A collaborative research team has developed the world's first AI-based optical diagnostic platform that enables rapid and ...

Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022 Effective diagnosis, prognostication, ...

Fujirebio is launching a human cerebrospinal fluid (CSF) assay in its continuing efforts to detect Alzheimer’s ...

Sequencing circulating tumor cell-free DNA (cfDNA) in cerebrospinal fluid (CSF) improved diagnosis, decision-making, and clinical care in pediatric and adolescent and young adult (AYA) patients with ...

A multitude of genes have been linked to the development of Alzheimer's disease. Specifically how those genes might influence the progression of neurodegeneration remains something of a black box ...

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 CSF assay for the fully automated LUMIPULSE® G immunoassay analyzers. Th ...

Cerebrospinal fluid (CSF) leaks represent a significant clinical challenge, marked by the aberrant escape of CSF from its usual confines into adjacent structures such as the paranasal sinuses, which ...

The growth of the Cerebrospinal Fluid (CSF) Management Market is primarily driven by the rising incidence of neurological disorders such as hydrocephalus, brain injuries, and spinal cord conditions, ...

Cerebrospinal fluid is a watery liquid that continually circulates through the brain’s ventricles and around the surface of the brain and spinal cord. It acts like a cushion that helps protect the ...